RhumbLine Advisers’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $725K | Sell |
71,431
-17,322
| -20% | -$176K | ﹤0.01% | 2425 |
|
|
2025
Q1 | $495K | Sell |
88,753
-4,566
| -5% | -$25.5K | ﹤0.01% | 2582 |
|
|
2024
Q4 | $753K | Buy |
93,319
+4,072
| +5% | +$32.9K | ﹤0.01% | 2403 |
|
|
2024
Q3 | $915K | Sell |
89,247
-3,455
| -4% | -$35.4K | ﹤0.01% | 2308 |
|
|
2024
Q2 | $655K | Buy |
92,702
+32,402
| +54% | +$229K | ﹤0.01% | 2476 |
|
|
2024
Q1 | $829K | Buy |
60,300
+2,396
| +4% | +$32.9K | ﹤0.01% | 2356 |
|
|
2023
Q4 | $533K | Sell |
57,904
-677
| -1% | -$6.23K | ﹤0.01% | 2623 |
|
|
2023
Q3 | $354K | Buy |
58,581
+6,676
| +13% | +$40.4K | ﹤0.01% | 2831 |
|
|
2023
Q2 | $403K | Buy |
+51,905
| New | +$403K | ﹤0.01% | 2828 |
|
|
2022
Q2 | – | Sell |
-38,871
| Closed | -$208K | – | 3196 |
|
|
2022
Q1 | $208K | Buy |
38,871
+2,921
| +8% | +$15.6K | ﹤0.01% | 2749 |
|
|
2021
Q4 | $528K | Sell |
35,950
-402
| -1% | -$5.9K | ﹤0.01% | 2487 |
|
|
2021
Q3 | $760K | Buy |
36,352
+2,578
| +8% | +$53.9K | ﹤0.01% | 2352 |
|
|
2021
Q2 | $597K | Buy |
33,774
+11,287
| +50% | +$200K | ﹤0.01% | 2487 |
|
|
2021
Q1 | $551K | Buy |
22,487
+495
| +2% | +$12.1K | ﹤0.01% | 2445 |
|
|
2020
Q4 | $744K | Buy |
21,992
+13,308
| +153% | +$450K | ﹤0.01% | 2267 |
|
|
2020
Q3 | $217K | Sell |
8,684
-1,425
| -14% | -$35.6K | ﹤0.01% | 2652 |
|
|
2020
Q2 | $341K | Buy |
+10,109
| New | +$341K | ﹤0.01% | 2519 |
|